Novartis to use gene editing tool with CAR-T therapies

Novartis has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using the CRISPR genome editing technology. It simultaneously entered a deal with Caribou Biosciences for the development of drug discovery tools in the nascent field.

Novartis has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using the CRISPR genome editing technology. It simultaneously entered a deal with Caribou Biosciences for the development of drug discovery tools in the nascent field.

"CRISPR has the potential to open a new branch of medicine, editing the genome to cure disease," stated Mark Fishman,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip